All Press Releases First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-2522 December, 2025 Xinnate Completes Oversubscribed Share Issue of SEK 38,5m18 December, 2025 Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa10 December, 2025
